PharmaMar is a Spanish biopharmaceutical company specializing in oncology drugs derived from marine organisms, with commercial products such as trabectedin (Yondelis) and a pipeline of marine-inspired anticancer candidates. It combines in-house R&D from marine natural products with global commercialization and partnerships. Its niche is hard-to-treat cancers and novel mechanisms of action rooted in ocean biodiversity rather than conventional small-molecule screening alone.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 38.9 | — | -4 | — |
| Q2 2025 | 56.4 | — | 23.4 | — |
| Q4 2025 | 128.3 | — | 55.6 | — |
| Q1 2026 | 42.9 | 10.4% | 1.5 | — |
| Q2 2026 | 49.6 | -12% | -1 | -104.2% |
All markets — KeepWinning global stock screener
Other companies on Bolsa de Madrid: Faes Farma, S.A. (FAE), Castellana Properties Socimi, S.A. (YCPS), GMP Property SOCIMI, S.A. (YGMP), Atresmedia Corporación de Medios de Comunicación, S.A. (A3M), Cox Infrastructure Group, S.A. (COXG), Prosegur Cash, S.A. (CASH)